Mylan lowered its 2017 earnings per share estimate by 5% from $5.17 to $4.93 and its 2018 estimate by 10% from $5.78 to $5.21. Mylan N.V. The business's revenue for the quarter was up 15.7% compared to the same quarter a year ago. Conning Inc. raised its position in shares of Mylan N.V.by 1.3% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company's stock valued at $162,765,000 after buying an additional 1,888,905 shares during the last quarter.
Mylan's net earnings rose 67 per cent to $297m, or 55 cents per share. The price of the life-saving tool has reportedly seen an increase of 500 percent in 10 years, but now, it looks like this has backfired on the company. Bank of Nova Scotia now owns 10,525 shares of the company's stock valued at $410,000 after buying an additional 196 shares in the last quarter. Cleararc Capital Inc. boosted its position in shares of Mylan N.V.by 0.6% in the first quarter. Hedge funds and other institutional investors own 70.19% of the company's stock.
Shares of Mylan N.V. About 3.07 million shares traded. The firm has a market cap of $17.19 billion, a PE ratio of 32.05 and a beta of 1.27. The firm's 50-day moving average is $37.74 and its 200 day moving average is $39.09. Mylan N.V. has a 1-year low of $29.58 and a 1-year high of $49.42. Mylan N.V. also was the recipient of unusually large options trading on Monday. Traders acquired 9,410 call options on the company. This represents an increase of 589% compared to the average daily volume of 2,749 call options. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. Analysts had expected total revenue of $3.03 billion. Mylan N.V. The company's revenue was up 15.7% compared to the same quarter a year ago. Equities research analysts predict that Mylan N.V. will post $5.12 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: "Mylan N.V. (NASDAQ:MYL) Shares Bought by Aperio Group LLC" was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of United States and worldwide copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/10/state-of-alaska-department-of-revenue-increases-stake-in-mylan-n-v-myl-updated.html.
MYL has been the subject of a number of research reports. The stock of Mylan N.V. (NASDAQ:MYL) has "Buy" rating given on Tuesday, July 28 by Deutsche Bank. The stock of Mylan N.V. (NASDAQ:MYL) earned "Outperform" rating by Leerink Swann on Wednesday, May 4. Cantor Fitzgerald set a $34.00 price objective on shares of Mylan N.V. and gave the company a "hold" rating in a report on Wednesday.
Mylan N.V. (MYL) now has P/E (Price to Earnings) ratio of 31.68 while the company's industry has 31.4 P/E and the sector P/E is 33.69.
Earnings, adjusted for non-recurring costs, came to $1.10 per share, well below the per-share estimates of $1.18 that Wall Street was seeking, according to a survey by Zacks Investment Research. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating.
Mylan also said it expects competition to erode prices for its generic drugs, by a rate in the mid-single digits globally and high-single digits in North America. Also, insider Anthony Mauro sold 10,000 shares of the business's stock in a transaction on Friday, June 9th. Following the transaction, the insider now owns 140,653 shares in the company, valued at approximately $5,626,120. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now owns 799,855 shares of the company's stock, valued at approximately $31,994,200. The disclosure for this sale can be found here.
"This is providing investors an opportunity to differentiate between pharmaceutical companies focused exclusively on generics and/or specialty medicines and those capable of delivering a broad and diverse portfolio across multiple channels in various geographies, which remains Mylan's strategy".
Plans to divest Medis, an Icelandic unit that develops generics for other companies, and its respiratory products would follow other pending disposals including its women's health business and European oncology and pain treatments.